322 related articles for article (PubMed ID: 37446316)
1. Mouse Models to Examine Differentiated Thyroid Cancer Pathogenesis: Recent Updates.
Choi HR; Kim K
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446316
[TBL] [Abstract][Full Text] [Related]
2. Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Patrizio A; Paparo SR; Marone G; Galdiero MR; Guglielmi G; Foddis R; Cristaudo A; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():203-216. PubMed ID: 32569821
[TBL] [Abstract][Full Text] [Related]
3. Management of pediatric differentiated thyroid cancer: An overview for the pediatric oncologist.
Prasad PK; Mahajan P; Hawkins DS; Mostoufi-Moab S; Venkatramani R
Pediatr Blood Cancer; 2020 Jun; 67(6):e28141. PubMed ID: 32275118
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Models of Follicular Cell-Derived Thyroid Cancer: An Overview from Cancer Cell Lines to Mouse Models.
Jeon MJ; Haugen BR
Endocrinol Metab (Seoul); 2022 Dec; 37(6):830-838. PubMed ID: 36604954
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
[No Abstract] [Full Text] [Related]
6. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
Raue F; Frank-Raue K
Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
[TBL] [Abstract][Full Text] [Related]
7. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
[TBL] [Abstract][Full Text] [Related]
8. Lessons from mouse models of thyroid cancer.
Kim CS; Zhu X
Thyroid; 2009 Dec; 19(12):1317-31. PubMed ID: 20001715
[TBL] [Abstract][Full Text] [Related]
9. Older patients with differentiated thyroid cancer exhibit more aggressive pathological characteristics than younger patients.
Johar J; Britton H; Wiseman SM
Can J Surg; 2020 Feb; 63(1):E69-E70. PubMed ID: 32031767
[TBL] [Abstract][Full Text] [Related]
10. Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
Thyroid; 2018 Aug; 28(8):976-981. PubMed ID: 29848239
[TBL] [Abstract][Full Text] [Related]
11. Death from thyroid cancer of follicular cell origin.
Wu HS; Young MT; Ituarte PH; D'Avanzo A; Duh QY; Greenspan FS; Loh KC; Clark OH
J Am Coll Surg; 2000 Dec; 191(6):600-6. PubMed ID: 11129807
[TBL] [Abstract][Full Text] [Related]
12. Genomic Characterization of Differentiated Thyroid Carcinoma.
Song YS; Park YJ
Endocrinol Metab (Seoul); 2019 Mar; 34(1):1-10. PubMed ID: 30912334
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid.
Ito Y; Miyauchi A
Endocr J; 2009; 56(2):177-92. PubMed ID: 18703852
[TBL] [Abstract][Full Text] [Related]
14. Approach to and treatment of differentiated thyroid carcinoma.
Pacini F; Castagna MG
Med Clin North Am; 2012 Mar; 96(2):369-83. PubMed ID: 22443981
[TBL] [Abstract][Full Text] [Related]
15. Finding the Optimal Age Cutoff for the UICC/AJCC TNM Staging System in Patients with Papillary or Follicular Thyroid Cancer.
van Velsen EFS; Visser WE; Stegenga MT; Mäder U; Reiners C; van Kemenade FJ; van Ginhoven TM; Verburg FA; Peeters RP
Thyroid; 2021 Jul; 31(7):1041-1049. PubMed ID: 33487121
[No Abstract] [Full Text] [Related]
16. Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification.
Soares P; Póvoa AA; Melo M; Vinagre J; Máximo V; Eloy C; Cameselle-Teijeiro JM; Sobrinho-Simões M
Endocr Pathol; 2021 Mar; 32(1):44-62. PubMed ID: 33651322
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance.
Acquaviva G; Visani M; Repaci A; Rhoden KJ; de Biase D; Pession A; Giovanni T
Histopathology; 2018 Jan; 72(1):6-31. PubMed ID: 29239040
[TBL] [Abstract][Full Text] [Related]
18. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
19. Well differentiated follicular thyroid neoplasia: impact of molecular and technological advances on detection, monitoring and treatment.
Gianoukakis AG; Giannelli SM; Salameh WA; McPhaul LW
Mol Cell Endocrinol; 2011 Jan; 332(1-2):9-20. PubMed ID: 21094678
[TBL] [Abstract][Full Text] [Related]
20. Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice.
Pringle DR; Vasko VV; Yu L; Manchanda PK; Lee AA; Zhang X; Kirschner JM; Parlow AF; Saji M; Jarjoura D; Ringel MD; La Perle KM; Kirschner LS
J Clin Endocrinol Metab; 2014 May; 99(5):E804-12. PubMed ID: 24512487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
